Which specific programs or drug targets at Neurocept are publicly linked to Dr Paul Cox's research or leadership?
Executive summary
Available public reporting links Dr. Paul Alan Cox to research programs at Brain Chemistry Labs / The Institute for EthnoMedicine focused on “tangle” neurodegenerative diseases (Alzheimer’s, ALS, Parkinson’s), investigations into dietary and environmental causes (Ogimi diet, Guam lytico‑bodig neurotoxin), and early diagnostic/anti‑tangle approaches, but the provided sources do not demonstrate any concrete, public program or molecular drug target at the company Neurocept that is directly run by or scientifically led by Cox [1] [2] [3] [4].
1. What Cox publicly leads: anti‑tangle research and diagnostic efforts
Reporting and institutional pages identify Paul Cox as Executive Director of Brain Chemistry Labs and frame his team’s objective as finding ways to stop protein tangles in the brain and to create diagnostics and treatments for Alzheimer’s, ALS and Parkinson’s — what the group calls “tangle diseases” — work described as leading to new prevention, diagnosis and slowing of progression [1] [5] [2].
2. The research threads Cox is publicly associated with: diet, toxins, and ethnobotany
Sources characterize Cox’s approach as ethnobotanical and ecology‑informed: he applies indigenous knowledge and non‑traditional lines of inquiry (including studies of the Ogimi diet and investigations into a Guam‑linked neurotoxin historically called lytico‑bodig) as leads for novel therapeutics and diagnostics, and Brain Chemistry Labs promotes symposiums and publications consistent with those lines of inquiry [4] [2] [3] [6].
3. What is not supported by the provided reporting: direct Neurocept program leadership or named molecular targets
None of the supplied documents identify a Neurcept program, proprietary molecule, receptor target, or specific pharmacological candidate at Neurocept that is publicly declared to be developed under Cox’s research or leadership; the explicit company‑level linkage between Paul Cox and Neurocept—i.e., named drug candidates, INDs, or target proteins at Neurocept—does not appear in the provided sources [4] [2] [3] [7].
4. Apparent marketing overlap and contested claims
Consumer commentary and review pages assert that Dr. Cox’s name and voice appear in online marketing for a product called “Neurocept,” with at least one review alleging misleading advertising that invoked Cox and other figures — but these are customer complaints on a review site rather than documentation of formal scientific collaboration, and the reporting collection contains no Neurocept press release, regulatory filing, or peer‑reviewed paper tying Cox’s laboratory programs to Neurocept’s documented drug targets [7].
5. Interpretive balance and limits of the record
In sum, public materials supplied here substantiate Cox’s leadership of a research program aimed at preventing and diagnosing protein‑tangle neurodegeneration and exploring ethnobotanical and dietary/toxicologic leads (Ogimi diet, Guam neurotoxin), but do not substantiate a public, programmatic connection between those efforts and Neurocept’s internal drug‑development programs or named drug targets; absence of evidence in these sources is not evidence of absence, and verifying any corporate R&D link would require Neurocept disclosures, regulatory filings, or primary collaboration documents that are not present among the provided records [1] [2] [3] [7].